Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

被引：0

作者：

Capuozzo, Maurizio ^{[1
]}

Santorsola, Mariachiara ^{[2
]}

Ianniello, Monica ^{[3
]}

Ferrara, Francesco ^{[1
]}

Zovi, Andrea ^{[4
]}

Petrillo, Nadia ^{[3
]}

Castiello, Rosa ^{[3
]}

Fantuz, Maria Rosaria ^{[3
]}

Ottaiano, Alessandro ^{[2
]}

Savarese, Giovanni ^{[3
]}

机构：

[1] ASL Naples 3, Coordinamento Farmaceut, I-80056 Ercolano, Italy

[2] IRCCS G Pascale, Ist Nazl Tumori Napoli, Via M Semmola, I-80131 Naples, Italy

[3] Ctr Polidiagnost Strumentale Srl, AMES, Via Padre Carmine Fico 24, I-80013 Casalnuovo Di Napoli, Italy

[4] Minist Hlth, Viale Giorgio Ribotta 5, I-00144 Rome, Italy

来源：

DISEASES | 2024年 / 12卷 / 05期

关键词：

prostate cancer; androgen-deprivation therapy; immunotherapy; PARP inhibitors; precision medicine; PHASE-III TRIAL; SIPULEUCEL-T; DOUBLE-BLIND; PLUS STANDARD; OPEN-LABEL; CASTRATION; IPILIMUMAB; IMMUNOTHERAPY; ENZALUTAMIDE; MULTICENTER;

D O I：

10.3390/diseases12050087

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.

引用

页数：22

共 50 条

[31] Treatment strategies in low-volume metastatic castration-resistant prostate cancer
Wei, Xiao X.
Ko, Eric C.
Ryan, Charles J.
CURRENT OPINION IN UROLOGY, 2017, 27 (06) : 596 - 603
[32] Highlights of recent research focused on the treatment of advanced prostate cancer
Gourdin, Theodore
CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 218 - 222
[33] SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
Gonzalez del Alba, A.
Mendez-Vidal, M. J.
Vazquez, S.
Castro, E.
Climent, M. A.
Gallardo, E.
Gonzalez-Billalabeitia, E.
Lorente, D.
Maroto, J. P.
Arranz, J. A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (05) : 969 - 979
[34] The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
Pagliuca, Martina
Buonerba, Carlo
Fizazi, Karim
Di Lorenzo, Giuseppe
DRUGS, 2019, 79 (04) : 381 - 400
[35] Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation
Beebe-Dimmer, Jennifer L.
Ruterbusch, Julie J.
Cooney, Kathleen A.
Bolton, Adam
Schwartz, Kendra
Schwartz, Ann G.
Heath, Elisabeth
CANCER MEDICINE, 2019, 8 (06): : 3325 - 3335
[36] Recent advances revolutionize treatment of metastatic prostate cancer
Madan, Ravi A.
Arlen, Philip M.
FUTURE ONCOLOGY, 2013, 9 (08) : 1133 - 1144
[37] Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
Adamaki, Maria
Zoumpourlis, Vassilios
CANCERS, 2021, 13 (02) : 1 - 23
[38] Targeted nanomedicine modalities for prostate cancer treatment
Cohen, Lital
Livney, Yoav D.
Assaraf, Yehuda G.
DRUG RESISTANCE UPDATES, 2021, 56
[39] Emerging agents for the therapy of advanced prostate cancer
Hathaway, Amanda R.
Baker, Mary Katherine
Sonpavde, Guru
FUTURE ONCOLOGY, 2015, 11 (20) : 2775 - 2787
[40] Ipilimumab in the treatment of prostate cancer
Reese, Zachary
Straubhar, Ali
Pal, Sumanta K.
Agarwal, Neeraj
FUTURE ONCOLOGY, 2015, 11 (01) : 27 - 37

← 1 2 3 4 5 →